Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	12 Months Ended			9 Months Ended	3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2012	Mar. 19, 2012
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:
Equity-based compensation expense	$ 807	$ 401	$ 143
Cash flows from financing activities:
Cash and cash equivalents, beginning of period	11,986
Cash and cash equivalents, end of period	78,009	11,986
Successor [Member]
Cash flows from operating activities:
Net (loss)	3,070	338		(12,353)
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:
Amortization of bond premium or discount	1,663	2,309		1,837
Net realized (gain) loss on sale of investments	(436)	1,575		(2,747)
Unrealized (gain) loss on trading securities	774	3,492		1,410
Equity-based compensation expense	807	401		143
Changes in assets and liabilities:
Accrued investment income	634	588		615
Other assets	586	338		1,589
Change in cash equivalents held in trust	21,971	(16,074)		9,230
Change in restricted cash	(2,332)	25,054		(25,169)
Losses and loss adjustment reserves	(25,367)	(38,210)		(58,486)
Losses payable	(1,821)	377		(5,445)
Unearned premiums	(300)	1,169		(184)
Accrued ceding commission expense	(58)	(34)		(330)
Accrued interest on notes payable	(805)	(333)		1,476
Loss contract fair market value reserve	(33,770)	(5,898)		(10,847)
Other liabilities	1,803	682		(3,513)
Total adjustments	(36,651)	(24,564)		(90,421)
Net cash (used in) provided by operating activities:	(33,581)	(24,226)		(102,774)
Cash flows from investing activities:
Purchase of investments	(511,103)	(430,983)		(202,847)
Proceeds from sales and maturities of investments	667,262	482,275		234,096
Net cash provided by (used in) investing activities:	156,159	51,292		31,249
Cash flows from financing activities:
Proceeds from issuance of preferred stock and warrants to purchase common stock	22,572
Fees incurred relating to preferred stock and warrant issuance	(3,348)
Deferred offering costs	(1,497)	(1,071)
Notes payable – principal repayments	(78,890)	(36,294)		(2,064)
Notes payable – principal issued	4,608	5,524		8,336
Net cash provided by (used in) financing activities:	(56,555)	(31,841)		6,272
Increase (decrease) in cash and cash equivalents	66,023	(4,775)		(65,253)
Cash and cash equivalents, beginning of period	11,986	16,761		82,014
Cash and cash equivalents, end of period	78,009	11,986	16,761	16,761
Cash paid during the period:
Interest	18,272	9,707		3,699
Supplementary disclosure of non-cash investing and financing activities:
Notes payable issued in lieu of cash interest payments	4,608	5,524		8,336
Preferred deemed dividend recorded due to beneficial conversion feature	9,455
Predecessor [Member]
Cash flows from operating activities:
Net (loss)			(15,800)		(3,433)
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:
Amortization of bond premium or discount					523
Net realized (gain) loss on sale of investments					(176)
Unrealized (gain) loss on trading securities					(1,049)
Changes in assets and liabilities:
Accrued investment income					309
Other assets					(597)
Change in cash equivalents held in trust					7,209
Losses and loss adjustment reserves					(1,109)
Losses payable					1,662
Unearned premiums					(47)
Accrued ceding commission expense					137
Other liabilities					414
Total adjustments					7,276
Net cash (used in) provided by operating activities:					3,843
Cash flows from investing activities:
Purchase of investments					(38,506)
Proceeds from sales and maturities of investments					34,035
Net cash provided by (used in) investing activities:					(4,471)
Cash flows from financing activities:
Cash from reorganization activities					75,000
Net cash provided by (used in) financing activities:					75,000
Increase (decrease) in cash and cash equivalents					74,372
Cash and cash equivalents, beginning of period			7,642		7,642
Cash and cash equivalents, end of period					$ 82,014